– Progenics' Imaging Agent Correctly Identified the Presence of Primary Prostate Cancer in 100% of Phase I Study Subjects – Progenics Also Announces That Topline Data From a Recently Completed Phase II Trial of 1404 Will be Presented at ASCO GU in January 2014 TARRYTOWN, N.Y., Dec. 6, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company focused on the development of innovative approaches to targeting and treating prostate cancer, announced that findings from a Phase I study of its Imaging Agent, 1404, were presented today at the meeting of the Society for Urologic Oncology in Rockville, Maryland. The poster, entitled A Phase I Study of TC-99-M-MIP-1404 SPECT/CT to Identify and Localize High Grade Cancer in the Prostate Gland, was presented by Kevin Slawin, M.D., Director, Vanguard Urologic Institute, Memorial Hermann-TMC. "In this study, the presence of primary prostate cancer was correctly identified in eight of eight patients by SPECT/CT imaging with 1404," said Dr. Slawin. "An imaging agent with this high degree of accuracy has the potential to allow doctors and their patients to focus on the treatment of aggressive cancers while more conservatively managing low grade cancers." "The successful development of an initial and ongoing treatment plan for the management of prostate cancer is often handicapped by the inability to accurately assess the presence, location, grade and extent of the disease," said Hagop Youssoufian, M.Sc., M.D., Executive Vice President, Research & Development at Progenics. "Accurate diagnosis and staging is imperative to avoid overtreatment of indolent disease, with its potential life changing side effects, including incontinence and impotence, and the underestimation of aggressive disease. In this Phase I trial our imaging agent identified primary prostate cancer with a high degree of accuracy and, in addition, may have the ability to discriminate high grade prostate cancer from moderate and low grade disease. We believe this is the kind of information men suffering from prostate cancer and their doctors need in order to best manage their disease."